November 4, 2026 | TickerRoast Markets Analysis
Neurocrine Biosciences (Nasdaq: NBIX) closed up 13.42% at $164.85 on Tuesday, Nov 3, 2026, according to Equibles price data and StockTitan’s close wrap, the first full session after a third quarter in which net product sales topped $1 billion for the first time. Data as of the Nov 3, 2026 close.
What Happened: A Billion-Dollar Quarter
Neurocrine reported after the bell on Monday, Nov. 2. According to the company’s press release, also filed with the SEC, total revenue rose 41% to $1.123 billion from $795 million a year earlier. CEO Kyle Gano highlighted “net product sales exceeding $1 billion for the first time.”
The growth came from three products. Ingrezza, the tardive dyskinesia and Huntington’s chorea drug that still carries the business, generated $801 million, up 17%. Crenessity, for congenital adrenal hyperplasia, more than doubled to $211 million, up 115%. And Vykat XR, which came with the Soleno Therapeutics acquisition that closed in May 2026, added $107 million. Non-GAAP diluted EPS rose to $3.29 from $2.17, while GAAP diluted EPS was $1.96, compared with $2.04 a year earlier.
| Metric (Q3 2026) | Figure | Change / comment |
|---|---|---|
| Total revenue | $1,123M | +41% year over year |
| Ingrezza net sales | $801M | +17% |
| Crenessity net sales | $211M | +115% |
| Vykat XR net sales | $107M | acquired with Soleno (May 2026) |
| Non-GAAP diluted EPS | $3.29 | vs $2.17 |
| GAAP diluted EPS | $1.96 | vs $2.04 |
| 2026 Ingrezza guidance | $2.900B-$2.925B | raised from $2.825B-$2.875B |
Why It Moved: The Ingrezza Worry Eased
The fact base is straightforward. Neurocrine raised its 2026 Ingrezza sales guidance to $2.900 to $2.925 billion from $2.825 to $2.875 billion, and lowered its selling, general and administrative expense outlook, according to the release. Results also cleared Wall Street’s bar by a wide margin: Zacks, via Yahoo Finance, had expected EPS of $2.54 on revenue of $1.04 billion.
The reason the reaction was this strong, in my view, is what happened three months earlier. According to StockTitan, the stock fell 10.1% on July 30, the day the previous Ingrezza range was set, as investors worried that the franchise was maturing. Tuesday’s raise directly addressed that fear. That is my interpretation; the company did not frame it that way.
Analysts moved targets up, and their views are their own, not ours. According to MarketBeat, Canaccord Genuity raised its price target to $220 from $210 with a Buy rating. MarketBeat and Investing.com also reported Piper Sandler lifting its target to $215 from $210 (Overweight), RBC Capital to $190 from $187 (Outperform) and Morgan Stanley to $185 from $183 (Equal Weight).
Context: Healthcare Earnings Movers on a Mixed Day
The broader tape was split on Election Day. According to Yahoo Finance market data, the S&P 500 closed up 0.36% at 7,568.92 on Nov 3, 2026, the Nasdaq Composite gained 0.83% to 25,372.01 on a rebound in chip stocks, and the Dow Jones Industrial Average slipped 0.38% to 51,786.72, weighed down by Apple. Neurocrine was one of several healthcare names reacting to earnings: RTTNews listed SI-BONE, Rockwell Medical and PTC Therapeutics among the day’s other notable healthcare gainers, while StockTitan’s wrap showed Stevanato Group down more than 28% on a GLP-1-related revenue warning.
For perspective, the jump did not take the stock to a new high. Equibles data put the 52-week closing high at about $185.50, and MarketBeat’s figures put the open at $159.00, a gap up from Monday’s $145.35 close. Before Tuesday, Zacks noted the shares were up just over 2% year to date.
The chart above shows the last six months of trading with moving averages, volume and RSI, using Yahoo Finance data. Tuesday’s session appears as the final candle.
What to Watch: R&D Day and the 2027 Readouts
The pipeline is the next chapter. According to the press release, Neurocrine will hold an R&D Day in New York on Dec. 15, 2026. It has started a Phase 1 study of NBIP-‘1968, a GLP-1/GIP/glucagon triple agonist for obesity, and a Phase 2 study of the muscarinic agonist NBI-‘567 as add-on therapy for cognitive impairment in Alzheimer’s disease. Phase 3 data for osavampator in major depressive disorder and direclidine in schizophrenia are expected in 2027. One balance-sheet detail worth tracking: StockTitan reports cash of about $790 million at Sept. 30, down from $2.54 billion at the end of 2025, reflecting the Soleno deal.
The quarter showed that Neurocrine is no longer a one-drug story. The upcoming readouts will show whether the pipeline can carry that diversification further.
Disclaimer: This article is for informational and entertainment purposes only and does not constitute investment, financial, legal or tax advice, nor a recommendation or solicitation to buy or sell any security. Market data are as of the stated close and may be delayed or revised; sources are cited above. Past performance does not guarantee future results. Investing involves risk, including the possible loss of capital. Do your own research and consult a licensed financial advisor before making any investment decision. TickerRoast and its authors may not hold positions in the securities mentioned and receive no compensation from the companies discussed.
Sources
- Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results — PR Newswire
- Form 8-K exhibit: Q3 2026 earnings release — SEC EDGAR
- Neurocrine Q3 earnings: revenue rises 41% to $1.1B — StockTitan
- NBIX price history — Equibles
- Neurocrine Biosciences Shares Gap Up on Strong Earnings — MarketBeat
- NBIX gets price target bump from Canaccord Genuity — MarketBeat
- Why is Neurocrine Biosciences stock surging today? — Investing.com
- NBIX Beats on Q3 Earnings & Sales, Raises ’26 Ingrezza Sales View — Zacks via Yahoo Finance
- Healthcare stocks move higher — RTTNews
- Stock Market Today Live, November 3, 2026 — StockTitan
- Stock market today: Dow slips, S&P and Nasdaq gain as chip stocks rally — Yahoo Finance
Market data: Yahoo Finance, close of 2026-11-03. Charts generated by TickerRoast from this data.
Disclaimer: This article is for informational and educational purposes only. It provides general financial and business analysis and does not constitute investment advice, a personal recommendation, a recommendation to buy, sell or hold any security, or an offer to transact in any financial instrument. Information is based on publicly available sources as of November 4, 2026 and market data as of the 2026-11-03 close (Yahoo Finance). Past performance is not a reliable indicator of future results; forecasts are uncertain and actual results may differ materially. Investing in shares involves risk, including the loss of capital. The publisher does not guarantee the accuracy or completeness of the information and accepts no responsibility for investment decisions made on the basis of this article. Readers should consult official company disclosures, conduct their own research and, where appropriate, seek advice from a licensed financial adviser. Any relevant financial interests held by the author or publisher in the securities mentioned are disclosed where applicable. This article was prepared with the assistance of AI tools and is based on the sources listed above.
Anonymous reader poll, just for fun. Not investment advice.
Read next
Get the daily market briefing
The stories that move markets, in your inbox every trading day at 9 a.m. ET. Free, unsubscribe anytime.
